Personalized Medicine: New Insights into Treating Cancer and Multiple Comorbidities

A special issue of Journal of Personalized Medicine (ISSN 2075-4426). This special issue belongs to the section "Personalized Therapy and Drug Delivery".

Deadline for manuscript submissions: closed (31 March 2025) | Viewed by 1391

Special Issue Editors


E-Mail Website
Guest Editor
Department of Nursing, International Hellenic University, 570 01 Thessaloniki, Greece
Interests: cancer nursing; radiotherapy and cancer; inmmunotherapy and cancer; breast cancer; lung cancer; cancer and diabetes
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Personalized medicine is revolutionizing the way we approach the treatment of cancer, particularly when it coexists with other complex diseases. By tailoring medical care to the unique genetic, environmental, and lifestyle characteristics of each patient, personalized medicine enables healthcare providers to predict which treatments will be most effective, with greater accuracy. This approach is especially crucial in cancer care, where the precise targeting of therapies can significantly improve outcomes while minimizing harmful side effects and drug interactions.

In the context of managing multiple diseases, personalized medicine becomes even more critical. Patients with cancer often face a challenging landscape of coexisting conditions, such as diabetes, hypertension, and cardiovascular diseases. These comorbidities not only complicate treatment decisions but also require a highly coordinated and individualized care plan that can address the intricate interactions between various health conditions and their treatments. By focusing on the distinct profile of each patient, personalized medicine aims to not only enhance the efficacy of cancer therapies but also improve overall quality of life, ensuring that the complexities of managing multiple diseases are effectively addressed.

The simultaneous treatment of cancer and multiple diseases, furthermore, presents significant challenges due to the complex interactions between various health conditions and their respective therapies, underscoring the fact that patients with these overlapping health concerns require a tailored, multidisciplinary approach to care that considers the potential for drug interactions, compounded side effects, and the cumulative impact on their overall health. The variability in disease progression and individual patient responses further complicates management, underscoring the urgent need for ongoing research and innovation. Thus, this Special Issue aims to address these challenges by providing a platform for research that can lead to more effective, personalized treatment strategies for patients with cancer and multiple comorbidities. Our Special Issue seeks to gather cutting-edge research articles and comprehensive reviews that delve into the intersection of cancer treatment and personalized medicine in the context of multiple diseases. We welcome contributions that highlight innovative approaches, successful case studies, and in-depth analyses that can advance the field and lead to better patient care.

Dr. Ioannis Tsamesidis
Dr. Maria Lavdaniti
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Personalized Medicine is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cancer
  • quality of life
  • autoimmune diseases
  • diabetes

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 1186 KiB  
Article
Anxiety, Depression, and Quality of Life in Women with Breast Cancer and Type 2 Diabetes: A Pilot Study in North Greece
by Maria Parpori, Ioannis Tsamesidis, Evangelos Karamitrousis, Aikaterini Giakidou, Evangelia Kroustalidou, Polixeni Liamopoulou and Maria Lavdaniti
J. Pers. Med. 2024, 14(12), 1154; https://doi.org/10.3390/jpm14121154 - 17 Dec 2024
Viewed by 972
Abstract
Introduction: The incidence of breast cancer, as well as diabetes mellitus (DM), has continuously increased in recent years. The concurrent study of these diseases is particularly important, as there is a strong correlation between them due to hormonal, biochemical, and environmental factors. [...] Read more.
Introduction: The incidence of breast cancer, as well as diabetes mellitus (DM), has continuously increased in recent years. The concurrent study of these diseases is particularly important, as there is a strong correlation between them due to hormonal, biochemical, and environmental factors. Moreover, the underlying metabolic dysfunction in this case could affect the treatment of breast cancer, as well as overall survival. In addition, the relationship of these two diseases with depression is not well studied. Patients with DM and cancer patients both experience depressive symptoms that have an impact on their mental health, as well as their quality of life. Personalized medicine offers a potential solution to these challenges by tailoring treatments to individual patient profiles. The present study will attempt to fill a gap in the existing literature regarding the relationship of patients with concurrent breast cancer and DM experiencing depression. More specifically, it will attempt to answer the question of whether there is a strong correlation between breast cancer, DM, and mental health in patients from a large geographical division of the country. Methodology: This was a cross-sectional study. A total of 120 female patients participated in the research, 60 with type 2 diabetes mellitus (T2DM) (group B) and 60 with T2DM and breast cancer (group A). The DASS-21 questionnaire was used to determine their levels of anxiety and depression, and ADDQoL-19 was used to measure the patients’ quality of life. Results: Regarding quality of life, women with T2DM and breast cancer showed a better quality of life (QoL) than women with T2DM. Women who were retired (p = 0.025) and consequently postmenopausal (p = 0.035) demonstrated the highest levels of QoL, while stage III cancer patients had lower ADDQoL-19 scores. Regarding mental health, in the women from group A, a positive correlation of treatment with the occurrence of anxiety and depression (p = 0.034) and a negative correlation of cancer stage with mental health was observed. The women in group B (those with T2DM only) showed better mental health outcomes related to their treatment (p = 0.009). However, both married and unmarried women in this study experienced mental health burdens, with no significant difference between the two groups in terms of mental health impact. These findings suggest that marital status did not significantly influence the mental health of the participants in this study. Conclusions: Women with T2DM and breast cancer generally presented a better clinical picture than women with T2DM alone. Therefore, the comorbidity of these two diseases did not seem to negatively affect the quality of life and mental health of these women. Full article
Show Figures

Graphical abstract

Back to TopTop